News >

PVd Regimen Highlighted as New Standard in Relapsed/Refractory Myeloma

Published: Friday, Jul 13, 2018

 Paul Richardson, MD

Paul Richardson, MD
Findings from the phase III OPTIMISMM trial established the combination of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (PVd) as a new standard of care in patients with relapsed/refractory multiple myeloma with prior exposure to lenalidomide (Revlimid), said Paul Richardson, MD.

, Richardson discussed the combination’s efficacy and tolerability, as well as the possibility of pairing PVd with other agents to boost outcomes without increasing toxicity in multiple myeloma.

OncLive: Can you discuss the background of this study?

Richardson: We have demonstrated that there is synergy between immunomodulatory (IMiD) treatments and proteasome inhibitors. That's been a paradigm in myeloma treatment for some time.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication